Amphetamine psychosis: A model for studying the onset and course of psychosis

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  Hermens, Daniel F ^a   Lubman, Dan I ^b   Ward, Philip B ^c,d   Naismith, Sharon L ^a   Hickie, Ian B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CATECHOL METHYLTRANSFERASE; DYSBINDIN; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; PROTEIN INTERACTING WITH PROTEIN KINASE C;

ARTICLE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MODEL; EVENT RELATED POTENTIAL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LEARNING; MISMATCH NEGATIVITY; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; WORKING MEMORY;

EID: 61849088303     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02370.x     Document Type: Article

References (33)

1. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006; 7: 583-590.
2. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004; 9: 14-27,
3. Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008; 7: 68-83.
4. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000; 9: 28-37.
5. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473-1478.
6. Ross J, editor. Illicit drug use in Australia: epidemiology, use patterns and associated harm. 2nd ed. National Drug Strategy Monograph No. 63. Canberra: Commonwealth Department of Health and Family Services, 2007.
7. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and comorbidity of methamphetamine users with and without psychosis. Psychol Med 2003; 33: 1407-1414.
8. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003; 15: 317-325.
9. American Psychiatric Association. DSM-IV sourcebook. Washington, DC: APA, 1994.
10. Mathias S, Lubman D, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358-367.
11. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141-148.
12. Flaum M, Schultz SK. When does amphetamine-induced psychosis become schizophrenia? Am J Psychiatry 1996; 153: 812-815.
13. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13: 181-190.
14. Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry 2001; 178 Suppl: S18-S24.
15. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
16. Williams HJ, Owen MJ, O'Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull 2007; 33: 635-641.
17. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31: 301-313.
18. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-6191.
19. Suzuki A, Nakamura K, Sekine Y, et al. An association study between catechol-O-methyltransferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet 2006; 16: 133-138.
20. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-1127.
21. Bilder RM, Volavka J, Lachman HM, et al. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic clopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961.
22. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005; 76: 1-23.
23. Javitt DC, Shelley AM, Silipo G, et al. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry 2000; 57: 1131-1137.
24. Oades RD, Wild-Wall N, Juran SA, et al. Auditory change detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in patients with a first episode in adolescence, and patients 14 years after an adolescent illness-onset. BMC Psychiatry 2006; 6: 7.
25. Hosak L, Kremlacek J, Kuba M, et al. Mismatch negativity in methamphetamine dependence: a pilot study. Acta Neurobiol Exp (Wars) 2008; 68: 97-102.
26. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000; 14: 1-21.
27. Danion J, Huron C, Vidailhet P, et al. Functional mechanisms of episodic memory impairment in schizophrenia. Can J Psychiatry 2007; 52: 693.
28. Kraus MS, Keefe RS. Cognition as an outcome measure in schizophrenia. Br J Psychiatry 2007; 50 Suppl: S46-S51.
29. Scott J, Woods S, Matt G, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17: 275-297.
30. McKetin R, Mattick RP. Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend 1998; 50: 181-184.
31. Simon SL, Dacey J, Glynn S, et al. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat 2004; 27: 59-66.
32. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242.
33. Umbricht D, Koller R, Vollenweider FX, et al. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 2002; 51: 400-406.